Wondering if Nuvation Bio at around 8.66 is still a smart buy after its big run, or if most of the upside is already priced in? This article is designed to unpack that value question in plain English.

Nuvation Bio (NUVB) has quietly turned into one of the market’s stronger biotech movers, with the stock up about 78% over the past month and more than tripling year to date. See our latest analysis ...

Baystreet.ca News Commentary – The FDA issued multiple breakthrough approvals for oncology drugs in November 2025, marking a transformative month for cancer treatment with ...

Fintel reports that on December 11, 2025, HC Wainwright & Co. maintained coverage of Nuvation Bio (NYSE:NUVB) with a Buy ...

H.C. Wainwright raised the firm’s price target on Nuvation Bio (NUVB) to $18 from $10 and keeps a Buy rating on the shares. The firm cites its ...